Skip to main content

Table 1 Study characteristics

From: Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review

Study

Year

Country

Total (N = 388)

Study Characteristics

Tx A (n)

Tx B (n)

Aspirin dose per day

Study Design

Randomization

Son et al.

2011

US

106

Retrospective

N/A

IVIg (86)

IFX (20)

80-100 mg/kg until afebrile then 3-5 mg/kg

Youn et al.

2016

Korea

43

Prospective

+

IVIg (32)

IFX (11)

80-100 mg/kg until afebrile

Teraguchi et al.

2013

Japan

41

Prospective

+

IVIg (27)

IVMP (14)

30 mg/kg

Furukawa et al.

2008

Japan

63

Prospective

IVIg (19)

IVMP (44)

30 mg/kg tapered to 10 mg/kg then 5 mg/kg

Ogata et al.

2008

Japan

27

Retrospective

N/A

IVIg (14)

IVMP (13)

80-100 mg/kg

Miura et al.

2005

Japan

22

Prospective

+

IVIg (11)

IVMP (11)

 

Miura et al.

2011

Japan

74

Prospective

IVIg (74)

30 mg/kg until afebrile then 5 mg/kg until 8 weeks

Singh et al.

2015

India

12

Retrospective

N/A

IFX (12)

30 mg/kg until afebrile then 3–5 mg/kg